FDA Approved Expanded Access of Cancer Bioshield™ to treat Solid Tumor Lymphopenia

To date, this is the first treatment for lymphopenia, a depletion of critical lymphocytes responsible for immunogenic cell death.

Learn More

 

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic MOU

The signing of a strategic Memorandum of Understanding (MOU) will introduce the FDA-approved Cancer BioShield platform to Saudi Arabia and the broader Middle East

Learn More

 

QUILT-3.032 Data Shows Longest Duration of Response & Highest Cystectomy Avoidance in NMIBC

36 months of bladder preservation in over 80% of ANKTIVA® + BCG responders

Learn More

 

First Patient Dosed as Part of Recombinant BCG (rBCG) Expanded Access Program

With 60 sites launching, providers like U.S. Urology Partners are helping address the nationwide BCG shortage.

Learn More

 

European Medicines Agency Has Begun Assessing Marketing Authorization Application for ANKTIVA+BCG

Application is for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) and, if approved, would cover 27 countries in the European Union (EU)

Learn More

 

Researching Ways to Prevent Cancer

ImmunityBio is working with the National Cancer Institute (NCI) on the largest Lynch syndrome cancer prevention study in the U.S. People with hereditary Lynch syndrome can develop colorectal cancer decades earlier than average, and have increased risk of developing other cancer types.

Learn More

Click Here – Founder’s Vision Immunotherapy 2.0

Click Here – 2025 Investor Key Opinion Leader Conference

For inquiries regarding Dr. Patrick Soon-Shiong’s recent interview on BioShield, please click here for more information.

Solutions for Patients

Many cancer therapies, including radiation therapy, chemotherapy, CAR-T therapy, and B-cell immunotherapy, severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.
Learn More

Opportunities for Trial Investigators

The broad therapeutic potential and demonstrated safety of ImmunityBio’s immune-enhancing IL-15 superagonist Anktiva (N-803), engineered NK-92® cell-based therapies, and our next-generation adenovirus-vectored anti-cancer vaccines make them appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research. Interested clinicians and other are encouraged to contact ImmunityBio to find out how they may support discovery of future cancer treatments.
Learn More

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.
Learn More
Dr. Patrick Soon-Shiong
Global Chief Scientific and Medical Officer, ImmunityBio
At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both the innate and adaptive branches of the immune system, to facilitate the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease.
 

Smart Therapies for Difficult Diseases®

Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle offense” designed to deliver durable, complete responses in cancer and infectious diseases.

Our Science
Our Science

Investigational Cancer Therapies and Vaccines

ImmunityBio’s platforms address the entire immune system, harnessing the power of both innate and adaptive functions of the immune system by activation of ‘first responder’ natural killer (NK) cells, T cells, and macrophages, and establishment of immune memory by dendritic cells. We believe this comprehensive immunotherapy approach holds greater potential than CAR-T therapies or checkpoint inhibitors alone. We are also leveraging our established neoepitope prediction pipeline to predict which unique tumor-associated neoepitope peptides have the potential to trigger an effective, anti-tumor immune response when delivered to patients as a personalized vaccine. Clinical trials to assess the safety and efficacy of orchestrated use of these unique, complementary therapies and vaccine candidates are in progress across multiple tumor types.

Bladder Cancer Glioblastoma Lynch Syndrome Non-Hodgkin Lymphoma Non-Small Cell Lung Cancer Ovarian Cancer

Investigational Viral Therapies

Our recent findings from studies in HIV-infected patients show that cells infected with HIV can be exposed by our immune enhancer ANKTIVA to enable recognition and killing. This approach offers an opportunity for HIV patients to achieve a cure, and freedom from life-long anti-viral therapy. Tying viral infection and cancer together, we are developing a human papilloma virus (HPV) vaccine that has the potential to not only eradicate infection, but reduce the risk for HPV-associated cancers such as head/neck and cervical cancer.

HIV
See All Research

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us

A Robust Clinical Pipeline

We are applying our science and platforms, including the development of potential cancer vaccines, to treat cancers, as well as developing immuno- and cell therapies that we believe could sharply reduce or eliminate the need for standard high-dose chemotherapy.

See Pipeline
Pipeline

Latest News & Events

Visit Newsroom